<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01580605</url>
  </required_header>
  <id_info>
    <org_study_id>GHDA-1755</org_study_id>
    <nct_id>NCT01580605</nct_id>
  </id_info>
  <brief_title>French National Registry of Adults With Growth Hormone Deficiency Treated With Somatropin</brief_title>
  <official_title>Prospective, Longitudinal and National Follow-up Program of Adult Patients With Somatotropic Hormone Deficiency for Whom Substituting Treatment by Norditropin SimpleXx Was Started</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted in Europe. The aim of this study is to extract data from the French
      National Registry holding information about patients having initiated growth hormone therapy
      with the objective to describe patients receiving growth hormone therapy, assess efficacy and
      safety of somatropin (Norditropin® SimpleXx®) and evaluate treatment compliance.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Weight</measure>
    <time_frame>Once a year for 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Body composition</measure>
    <time_frame>Once a year for 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Waist:Hip Ratio</measure>
    <time_frame>Once a year for 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Body mass index (BMI)</measure>
    <time_frame>Once a year for 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>IGF-1 (Insulin-like growth factor 1) concentration</measure>
    <time_frame>Once a year for 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipids: Total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL) and triglycerides</measure>
    <time_frame>Once a year for 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose prescribed</measure>
    <time_frame>Once a year for 5 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">331</enrollment>
  <condition>Growth Hormone Disorder</condition>
  <condition>Adult Growth Hormone Deficiency</condition>
  <arm_group>
    <arm_group_label>Users of somatropin</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>somatropin</intervention_name>
    <description>Data are extracted from the French National Registry &quot;l'Observatoire National des Prescriptions et Consommations de Médicaments&quot; to where physicians report data about growth hormone treatment</description>
    <arm_group_label>Users of somatropin</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All adult patients with growth hormone deficiency and treated with Norditropin® SimpleXx
        (somatropin) for whom Norditropin® SimpleXx® has been initiated either before or during the
        registry inclusion period
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult with growth hormone deficiency

          -  Treated with Norditropin® SimpleXx (somatropin)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Lyon</city>
        <zip>69394</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2012</study_first_submitted>
  <study_first_submitted_qc>April 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2012</study_first_posted>
  <last_update_submitted>April 29, 2014</last_update_submitted>
  <last_update_submitted_qc>April 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endocrine System Diseases</mesh_term>
    <mesh_term>Dwarfism, Pituitary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

